Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
256 hedge funds and large institutions have $6.46B invested in Karuna Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 105 increasing their positions, 84 reducing their positions, and 60 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 84
11% less funds holding
Funds holding: 289 → 256 (-33)
21% less capital invested
Capital invested by funds: $8.16B → $6.46B (-$1.7B)
24% less call options, than puts
Call options by funds: $62.3M | Put options by funds: $82.5M
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
50% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$56.8M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$49.5M |
| 3 |
GA
General Atlantic
New York
|
+$48.8M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$34.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$21.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$81.8M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$61.5M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$29.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.6M |
| 5 |
HF
HRT Financial
New York
|
-$17.5M |
KRTX Hedge Fund Activity: Q3 2023 in Review
256 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q3 2023, worth a combined $6.46B — down 21% from $8.16B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of KRTX and 30 opened new positions — a net loss of 30 holders — while 84 trimmed existing stakes and 105 added.
The largest buyer was Point72 Asset Management, adding an estimated $56.8M. The largest seller was Lord, Abbett & Co, cutting an estimated $81.8M.
- 256 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q3 2023, down from 289 in Q2 2023.
- Funds reported $6.46B of Karuna Therapeutics, Inc. Common Stock stock for Q3 2023, down 21% quarter-over-quarter.
- 30 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q3 2023 and 60 closed out, a net change of -30 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q3 2023 was Point72 Asset Management, an estimated $56.8M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q3 2023 was Lord, Abbett & Co, an estimated $81.8M sold.
Based on aggregated 13F filings for Q3 2023.